# Ata Dtc Risk Stratification

> ATA DTC Initial Risk Stratification Tool

- Skill: `dromlakhani/ata-dtc-risk-stratification` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/ata-dtc-risk-stratification`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/ata-dtc-risk-stratification/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-21
- Page: https://skillmd.com/skills/dromlakhani/ata-dtc-risk-stratification

---


# ATA DTC Initial Risk Stratification Tool
**Source:** 2015 ATA Management Guidelines — ATA Modified 2009 Initial Risk Stratification System (Table 11).  
Haugen et al. Thyroid 2016;26(1). DOI: 10.1089/thy.2015.0020

---

## PURPOSE

The ATA risk tier (Low / Intermediate / High) is assigned at the time of **initial surgical pathology** and governs:
1. Whether RAI remnant ablation is indicated
2. Intensity of initial TSH suppression
3. Frequency and modality of follow-up
4. When and how to reclassify risk dynamically (see Dynamic Risk Stratification skill)

---

## STEP 1 — Collect Pathologic and Clinical Data

Before assigning tier, confirm:
- [ ] Histologic subtype (classic PTC, follicular variant PTC, FTC, Hürthle cell, tall cell, columnar, hobnail, etc.)
- [ ] Tumor size (largest focus in cm)
- [ ] Unifocal vs. multifocal
- [ ] Completeness of resection (R0, R1, R2)
- [ ] Extrathyroidal extension: none / microscopic (pT3a ETE) / gross (pT4)
- [ ] Lymph node status: clinical N0 / pN0 / pN1 (number, size of largest node, extranodal extension)
- [ ] Vascular invasion: none / minimal (≤3 foci) / extensive (≥4 foci)
- [ ] Distant metastases: none / suspected / confirmed
- [ ] BRAF mutation status (for PTMC with multifocality and ETE)
- [ ] Post-surgical serum Tg (while hypothyroid or after rhTSH)

---

## STEP 2 — Assign ATA Risk Tier

### ✅ ATA LOW Risk

**All of the following must apply:**

- Complete resection of macroscopic disease
- No local invasion (no microscopic or gross ETE)
- No regional or distant metastases
- No aggressive histologic subtype (tall cell, hobnail, columnar, diffuse sclerosing, solid/trabecular)
- No vascular invasion

**AND meets one of these histologic profiles:**

| Profile | Details |
|---|---|
| Intrathyroidal PTC | Clinical N0, or pN1 with ≤5 lymph node micrometastases, all <0.2 cm |
| Intrathyroidal encapsulated follicular-variant PTC (FV-PTC) | Completely encapsulated |
| Intrathyroidal well-differentiated FTC | Capsular invasion only, OR minimal vascular invasion (≤3 foci) |
| Intrathyroidal PTMC | Unifocal OR multifocal |

> **Estimated recurrence risk: ~1–2% for intrathyroidal PTC; <5% overall**

---

### ⚠️ ATA INTERMEDIATE Risk

**Any one of the following:**

| Feature | Notes |
|---|---|
| Microscopic extrathyroidal extension (pT3a) | Minimal/microscopic ETE into perithyroidal soft tissue |
| RAI-avid disease in the neck on first post-treatment whole body scan | Beyond thyroid bed |
| Aggressive histology | Tall cell, columnar, hobnail, diffuse sclerosing, solid/trabecular variants |
| PTC with vascular invasion | Any vascular invasion in PTC |
| Clinical N1 | LN involvement identified clinically or on imaging |
| pN1 — node-positive with >5 nodes involved, all <3 cm | Metastatic nodes but none ≥3 cm |
| Multifocal PTMC with ETE AND BRAF mutation | Both features must be present |

> **Estimated recurrence risk: ~3–8% (lower end) to 8–25% depending on features**

---

### 🔴 ATA HIGH Risk

**Any one of the following:**

| Feature | Notes |
|---|---|
| Gross (macroscopic) extrathyroidal extension (pT4) | Into major structures: strap muscles with direct invasion to adjacent structures |
| Incomplete surgical resection (R1/R2) | Gross residual or microscopically positive margins with known residual disease |
| Distant metastases (M1) | Lung, bone, or other sites |
| Postoperative serum Tg suggestive of distant metastases | Inappropriately elevated Tg not explained by remnant |
| pN1 with any single lymph node ≥3 cm | One or more metastatic nodes measuring ≥3 cm |
| FTC with extensive vascular invasion (≥4 foci) | Four or more foci of vascular invasion in FTC |

> **Estimated recurrence risk: >50%**

---

## STEP 3 — Map Risk Tier to Initial Management Decisions

| ATA Risk | RAI | TSH Suppression Goal | Initial Follow-up |
|---|---|---|---|
| **Low** | Not routinely recommended | TSH low-normal (0.5–2.0 mU/L) | Neck US at 6–12 months; Tg measurement |
| **Intermediate** | Consider (see RAI Decision Skill) | TSH slightly below normal (0.1–0.5 mU/L) | Neck US at 6–12 months; stimulated Tg if remnant ablation done |
| **High** | Routinely recommended (see RAI Decision Skill) | TSH <0.1 mU/L (aggressive suppression) | Imaging at 6–12 months; Tg/anti-Tg; further staging as needed |

---

## STEP 4 — Document for Dynamic Risk Reclassification

Record the initial ATA tier as a **baseline**. After 6–24 months:
- Reclassify using response-to-therapy categories (Excellent / Biochemical Incomplete / Structural Incomplete / Indeterminate)
- The initial tier informs prior probability; the response category drives ongoing management
- → Use the **ATA Dynamic Risk Stratification skill** for reclassification

---

## CLINICAL GUARDRAILS

- **ATA risk tier is a snapshot at surgery** — it will be updated as Tg trends and imaging emerge (dynamic risk)
- **Microscopic vs. gross ETE matters enormously** — microscopic ETE (into perithyroidal fat) = Intermediate; gross ETE (into strap muscle or beyond) = High
- **N1 staging is nuanced** — the number AND size of nodes drives tier (≤5 micrometastases <0.2 cm = Low; >5 nodes all <3 cm = Intermediate; any node ≥3 cm = High)
- **FTC with minimal vascular invasion** (1–3 foci) is Low risk; extensive vascular invasion (≥4 foci) is High risk — count the foci
- **PTMC multifocality alone is Low** — needs BOTH ETE and BRAF mutation to step up to Intermediate
- **Tg level at time of surgery** should be documented — high postoperative Tg may indicate residual/distant disease and upgrade effective risk even if pathology criteria are intermediate
- **This system applies to DTC (PTC + FTC)** — medullary and anaplastic thyroid cancers are managed under entirely different frameworks